Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases
Autor: | María Ángeles Blázquez-Cañamero, Mónica Vázquez-Díaz, J. Bachiller-Corral, Ana Rodriguez-Garcia, Carlos de la Puente, Alina Boteanu, Cristina Sobrino, Marta Valero, Carmen Medina-Quiñones, Carlos Guillén-Astete, Maria Jesus Garcia-Villanueva, M. Consuelo Diaz-Miguel, Jose Luis Morell-Hita, Marcelino Revenga, Carmen Larena, Sandra Garrote |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Immunology Population 03 medical and health sciences 0302 clinical medicine Rheumatology Risk Factors Rheumatic Diseases Internal medicine medicine Humans Immunology and Allergy 030212 general & internal medicine education Retrospective Studies 030203 arthritis & rheumatology education.field_of_study business.industry Abatacept COVID-19 medicine.disease Pneumonia Cohort Tumor Necrosis Factor Inhibitors Observational study Rituximab business Vasculitis medicine.drug |
Zdroj: | The Journal of Rheumatology. 48:1098-1102 |
ISSN: | 1499-2752 0315-162X |
Popis: | Objective.To describe the cohort of patients with inflammatory rheumatic diseases (IRD) hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the increased risk of severe coronavirus disease 2019 (COVID-19) in patients with no IRD.Methods.This is a retrospective single-center observational study of patients with IRD actively monitored in the Department of Rheumatology who were hospitalized due to COVID-19.Results.Forty-one (1.8%) out of 2315 patients admitted due to severe SARS-CoV-2 pneumonia suffered from an IRD. The admission OR for patients with IRD was 1.91 against the general population, and it was considerably higher in patients with Sjögren syndrome, vasculitis, and systemic lupus erythematosus. Twenty-seven patients were receiving treatment for IRD with corticosteroids, 23 with conventional DMARDs, 12 with biologics (7 rituximab [RTX], 4 anti–tumor necrosis factor [anti-TNF], and 1 abatacept), and 1 with Janus kinase inhibitors. Ten deaths were registered among patients with IRD. A higher hospitalization rate and a higher number of deaths were observed in patients treated with RTX (OR 12.9) but not in patients treated with anti-TNF (OR 0.9).Conclusion.Patients with IRD, especially autoimmune diseases and patients treated with RTX, may be at higher risk of severe pneumonia due to SARS-CoV-2 compared to the general population. More studies are needed to analyze this association further in order to help manage these patients during the pandemic. |
Databáze: | OpenAIRE |
Externí odkaz: |